Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Quality Cancer Center (MCGOP)
mi
from
Indianapolis, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Quality Cancer Center (MCGOP)
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Community Regional Cancer Center
mi
from
Indianapolis, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Community Regional Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Center for Cancer Care, Inc., P.C.
mi
from
New Albany, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Center for Cancer Care, Inc., P.C.
mi
from
New Albany, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
AP&S Clinic
mi
from
Terre Haute, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
AP&S Clinic
mi
from
Terre Haute, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Elkhart Clinic, LLC
mi
from
Elkhart, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Center for Cancer Care at Goshen Health System
mi
from
Goshen, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Center for Cancer Care at Goshen Health System
mi
from
Goshen, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Arnett Cancer Care
mi
from
Lafayette, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Arnett Cancer Care
mi
from
Lafayette, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
AP&S Clinic
mi
from
Terre Haute, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
AP&S Clinic
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Chemotherapy Toxicity Reduction Via Urea Cycle Support
Chemotherapy Toxicity Reduction Via Urea Cycle Support
Status: Enrolling
Updated:  12/8/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Chemotherapy Toxicity Reduction Via Urea Cycle Support
Chemotherapy Toxicity Reduction Via Urea Cycle Support
Status: Enrolling
Updated: 12/8/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Cancer Centers of Central Florida, PA
mi
from
Leesburg, FL
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Cancer Centers of Central Florida, PA
mi
from
Leesburg, FL
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Kapiolani Medical Center at Pali Momi
mi
from
Aiea, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Kapiolani Medical Center at Pali Momi
mi
from
Aiea, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Cancer Research Center of Hawaii
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Cancer Research Center of Hawaii
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
OnCare Hawaii, Incorporated - Lusitana
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
OnCare Hawaii, Incorporated - Lusitana
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Queen's Cancer Institute at Queen's Medical Center
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Queen's Cancer Institute at Queen's Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Straub Clinic and Hospital, Incorporated
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Straub Clinic and Hospital, Incorporated
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Hawaii Medical Center - East
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Hawaii Medical Center - East
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
OnCare Hawaii, Incorporated - Kuakini
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
OnCare Hawaii, Incorporated - Kuakini
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Tripler Army Medical Center
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Tripler Army Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Maui Memorial Medical Center
mi
from
Wailuku, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Maui Memorial Medical Center
mi
from
Wailuku, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Pacific Cancer Institute - Maui
mi
from
Wailuku, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Pacific Cancer Institute - Maui
mi
from
Wailuku, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Decatur Memorial Hospital Cancer Care Institute
mi
from
Decatur, IL
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Decatur Memorial Hospital Cancer Care Institute
mi
from
Decatur, IL
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Regional Cancer Center at Memorial Medical Center
mi
from
Springfield, IL
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Regional Cancer Center at Memorial Medical Center
mi
from
Springfield, IL
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Reid Hospital & Health Care Services
mi
from
Richmond, IN
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Reid Hospital & Health Care Services
mi
from
Richmond, IN
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
mi
from
Kansas City, KA
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Olathe Cancer Center
mi
from
Olathe, KA
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Olathe Cancer Center
mi
from
Olathe, KA
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Highland Clinic
mi
from
Shreveport, LA
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Highland Clinic
mi
from
Shreveport, LA
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
mi
from
Shreveport, LA
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
mi
from
Shreveport, LA
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Battle Creek Health System Cancer Care Center
mi
from
Battle Creek, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Battle Creek Health System Cancer Care Center
mi
from
Battle Creek, MI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Mecosta County Medical Center
mi
from
Big Rapids, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Mecosta County Medical Center
mi
from
Big Rapids, MI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Butterworth Hospital at Spectrum Health
mi
from
Grand Rapids, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Butterworth Hospital at Spectrum Health
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
CCOP - Grand Rapids
mi
from
Grand Rapids, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
CCOP - Grand Rapids
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Lacks Cancer Center at Saint Mary's Health Care
mi
from
Grand Rapids, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Lacks Cancer Center at Saint Mary's Health Care
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Mercy General Health Partners
mi
from
Muskegon, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Mercy General Health Partners
mi
from
Muskegon, MI
Click here to add this to my saved trials